Abstract 1847P
Background
With the increasing number of oncologic patients, consultation time per patient shortens, which negatively affects the doctor – patient relationship. Participation in psychotherapeutic groups can help patients gain trust in their treatment. The aim of this study is to quantify the effects of Simonton-training on the psychological state, quality of life and compliance in oncologic patients.
Methods
This survey was carried out at the University of Debrecen in the course of a 12-occasion-long Simonton training. A total of 27 patients in the psychotherapeutic group, and 63 patients in the control group were included in this study. Patients filled out an online questionnaire three times, before the training (t0), right after the training (t1), and again 3 months later (t2). The online questionnaire contained: The Hospital Anxiety and Depression Scale (HADS), WHO Quality of Life 5-item questionnaire (WHO QOL5), Morisky Medication Adherence Scale (MMAS-8) and five questions (5Q) about the general attitude towards their treatment and the trust in their oncologist. The distribution of continuous variables was statistically analysed with the Shapiro-Wilk test, and Wilcoxon test was used for comparisons between the case and control groups due to the non-normal distribution of the majority of variables.
Results
From t0 to t1, the Simonton group’s quality of life significantly increased (p=0,016), meanwhile the control group’s QoL didn’t change significantly (p=0,575). According to HADS scale, the Simonton group’s anxiety significantly decreased from t0 to t1 (p=0,0005), and the change of the control wasn’t significant (p=0,247). Depression values also showed a significant decrease for the Simonton group from t0 to t1 (p=0,003), whereas the control’s depression values didn’t change significantly (p=0,122). After psychotherapy, the Simonton group evaluated their therapy-related attitude better with the 5Q, than at t0 (p=0,026). During this time, the control’s value didn’t change significantly (p=0,532).
Conclusions
On the basis of this study the Simonton training had a positive impact on the patients' psychological state and their quality of life increased.
Clinical trial identification
DE RKEB/IKEB 5773-2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05